Predicting cytomegalovirus viremia….with CMV-specific T-cells

Predicting cytomegalovirus viremia after liver or intestine transplantation (LTx, ITx) with CMV-specific T-cell subsets

Identifying recipients who may experience CMV viremia after liver or intestine transplantation can potentially enhance decision making about the need for, and the timing and length of prophylactic antiviral therapy. Host immunity to CMV can be measured with CMV-specific T-cells, which express CD40 ligand or CD154(CD154+T-cells). Whether this immunity is best detected with a particular T-cell subset in clinical subjects is less well known.

Read more at: Abstract 28 on http://onlinelibrary.wiley.com/doi/10.1002/hep.28796/full